Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Theranostics"
DOI: 10.7150/thno.25487
Abstract: Rationale: Hepatocellular carcinoma (HCC) is an aggressive malignant solid tumor wherein CDK1/PDK1/β-Catenin is activated, suggesting that inhibition of this pathway may have therapeutic potential. Methods: CDK1 overexpression and clinicopathological parameters were analyzed. HCC patient-derived xenograft… read more here.
Keywords: cdk1 pdk1; treatment; pdk1 catenin; sorafenib ... See more keywords